Physician profile
Scott E Hansen
NPI 1164402897
$5,787.37
in general payments reported to CMS, 2019-2025
22 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $94.16 · 2021: $296 · 2022: $320 · 2023: $3,252 · 2024: $1,423 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $665 · Travel and Lodging: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $664.80 |
| Travel and Lodging | $135.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,154.90 | 2022-2024 | Davinci Xi |
| Hologic Sales and Service, LLC | $301.08 | 2019-2025 | Thinprep 2000 Processor, Novasure, Myosure Tissue Removal Device |
| Abbvie INC. | $248.66 | 2019-2025 | |
| Exeltis, USA INC. | $165.99 | 2021-2024 | Slynd |
| Organon LLC | $135.33 | 2021-2025 | Nexplanon |
| Roche Diagnostics Corporation | $118.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.66 | 2019-2023 | |
| Astellas Pharma US INC | $69.29 | 2024 | Veozah |
| Mayne Pharma Commercial LLC | $57.52 | 2021-2022 | |
| Therapeuticsmd, INC. | $55.69 | 2020-2021 | |
| Coopersurgical, INC. | $53.21 | 2019-2024 | Summit Doppler |
| Merck Sharp & Dohme LLC | $50.39 | 2020-2023 | Gardasil 9 |
| Meridian Bioscience INC. | $46.10 | 2019 | |
| Biogen, INC. | $41.17 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $39.17 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $31.96 | 2022-2025 | Prolia, Evenity |
| Daiichi Sankyo INC. | $24.93 | 2022 | |
| Evofem Biosciences, INC. | $21.94 | 2021 | |
| Novo Nordisk INC | $19.49 | 2024 | |
| Myovant Sciences INC. | $17.67 | 2021 | |
| Conmed Corporation | $16.46 | 2023 | Airseal |
| Shield Therapeutics INC | $16.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.